Medicine developmentWhat it doesAfimetoran, Beeline Medicines’ lead program, is a selective, small molecule, once-daily, equipotent TLR7/8 inhibitor with the potential to be a best-in-disease oral…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Who is involvedBacked by an established executive team, backed by world-class life science investors, each day Beeline Medicines is determined, existing shareholdersFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Why it mattersBeeline Medicines is using an upsized Series A to advance an autoimmune and inflammatory disease portfolio led by afimetoran for lupus and BLN-326 for diseases involving…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
